Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Barinthus Biotherapeutics Plc ADR (BRNS)

Barinthus Biotherapeutics Plc ADR (BRNS)
0.7600 unch (unch) 09:30 ET [NASDAQ]
0.7600 x 47 0.8940 x 3
Realtime by (Cboe BZX)
0.7600 x 47 0.8940 x 3
Realtime - - (-) -
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7600
Day High
0.7600
Open 0.7600
Previous Close 0.7600 0.7600
Volume 149 149
Avg Vol 14,507 14,507
Stochastic %K 22.07% 22.07%
Weighted Alpha -65.85 -65.85
5-Day Change -0.2900 (-27.62%) -0.2900 (-27.62%)
52-Week Range 0.7600 - 4.1591 0.7600 - 4.1591
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,658
  • Shares Outstanding, K 40,339
  • Annual Sales, $ 14,970 K
  • Annual Income, $ -61,070 K
  • EBIT $ -65 M
  • EBITDA $ -59 M
  • 60-Month Beta -0.77
  • Price/Sales 2.17
  • Price/Cash Flow N/A
  • Price/Book 0.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.49
  • Most Recent Earnings $-0.51 on 03/20/25
  • Next Earnings Date 05/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.37
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7600 unch
on 04/03/25
Period Open: 0.9700
1.1400 -33.33%
on 03/14/25
-0.2100 (-21.65%)
since 03/03/25
3-Month
0.7600 unch
on 04/03/25
Period Open: 1.1800
1.2792 -40.59%
on 01/07/25
-0.4200 (-35.59%)
since 01/03/25
52-Week
0.7600 unch
on 04/03/25
Period Open: 2.9100
4.1591 -81.73%
on 04/04/24
-2.1500 (-73.88%)
since 04/03/24

Most Recent Stories

More News
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.1975 (+3.95%)
BRNS : 0.7600 (unch)
FEMY : 1.2797 (-0.80%)
PERF : 1.7050 (-3.67%)
DRTS : 2.50 (-3.10%)
GIFT : 1.8850 (-0.26%)
ROYIF : 0.0448 (+121.78%)
ZCAR : 3.95 (-20.14%)
CLNN : 2.81 (-6.33%)
MIND : 5.25 (-9.79%)
PYPD : 2.61 (-3.69%)
TOVX : 1.1400 (-3.39%)
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.

BRNS : 0.7600 (unch)
Barinthus Biotherapeutics Announces Geoffrey Lynn, M.D., Ph.D. as New Chief Scientific Officer

Barinthus Biotherapeutics appoints Geoffrey Lynn as Chief Scientific Officer, succeeding Nadège Pelletier effective December 1, 2024.Quiver AI SummaryBarinthus Biotherapeutics plc has announced the promotion...

BRNS : 0.7600 (unch)
Barinthus Biotherapeutics Reports Significant Phase 2b HBV003 Trial Findings, Highlighting HBsAg Loss and Functional Cure Potential

Eight participants in the HBV003 trial achieved HBsAg loss; two met functional cure criteria. Results to be presented on November 18, 2024.Quiver AI SummaryBarinthus Biotherapeutics announced promising...

BRNS : 0.7600 (unch)
Arbutus Biopharma and Barinthus Bio Report Promising HBsAg Loss Results in Phase 2a IM-PROVE II Clinical Trial for Chronic HBV Infections

New data shows significant HBsAg declines in chronic hepatitis B patients treated with imdusiran, VTP-300, and low-dose nivolumab.Quiver AI SummaryArbutus Biopharma Corporation and Barinthus Biotherapeutics...

BRNS : 0.7600 (unch)
Fed Speaks, Canada Inflation on Lineup Next Week

Monday U.S. Economic Lookahead Home builder confidence index (Feb.) Featured Earnings ...

AOT.TO : 0.1200 (+9.09%)
FLOW.TO : 0.0900 (-10.00%)
SMT.TO : 0.86 (+8.86%)
DD : 69.11 (-8.16%)
CNM : 47.31 (-7.16%)
HQY : 83.47 (-5.94%)
HUMA : 1.4350 (-1.71%)
BRNS : 0.7600 (unch)

Business Summary

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus...

See More

Key Turning Points

3rd Resistance Point 0.9600
2nd Resistance Point 0.9200
1st Resistance Point 0.8400
Last Price 0.7600
1st Support Level 0.7200
2nd Support Level 0.6800
3rd Support Level 0.6000

See More

52-Week High 4.1591
Fibonacci 61.8% 2.8606
Fibonacci 50% 2.4595
Fibonacci 38.2% 2.0585
Last Price 0.7600
52-Week Low 0.7600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades